Form 4 for MLTX MoonLake Immunotherapeutics
Accepted 2025-10-09 00:00:00 ET · period of report 2025-10-08 · accession 0001213900-25-097594 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-09 | 2025-10-08 | MLTX | Bodenstedt Matthias | CFO | P - Purchase | $9.09 | +10.9K | 627.5K | +2% | +$98.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A ordinary shares, par value $0.0001 per share | 2025-10-08 | P | A | 10,870 | $9.09 | 627,536 | D | — | — | (F1) The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $9.085 to $9.091244. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. |